Clearside Biomedical (CLSDQ) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for May 30, 2025, with four key proposals for shareholder vote, including director elections, executive compensation, auditor ratification, and an amendment to increase authorized common stock shares from 200M to 400M.

• Voting is available online, by phone, mail, or in person, with a record date of April 1, 2025, for eligibility.

• Board recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Shareholders will vote on electing three directors, approving executive compensation (say-on-pay), ratifying Ernst & Young LLP as auditor, and amending the certificate of incorporation to increase authorized shares.

• Shareholder proposals and director nominations for the 2026 meeting must be submitted between January 30 and March 1, 2026.

• Board has established clear procedures for submitting shareholder proposals and director nominations, including compliance with universal proxy rules.

Board of directors and corporate governance

• Board consists of nine members, with a majority deemed independent under Nasdaq standards.

• Board leadership is separated, with an independent chairperson distinct from the CEO.

• Three standing committees: Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.

• Board and committees met regularly in 2024, with high attendance and executive sessions for independent directors.

• Board values diversity in skills, experience, and background, though no formal diversity policy exists.